Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients

A parainfluenza-3 outbreak in a SCT unit: sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality

(2011) A Hodson et al.   BONE MARROW TRANSPLANTATION

Treatment of Parainfluenza 3 Infection With DAS181 in a Patient After Allogeneic Stem Cell Transplantation

(2011) Y.-B. Chen et al.   CLINICAL INFECTIOUS DISEASES

A Safety Evaluation of DAS181, a Sialidase Fusion Protein, in Rodents

(2011) Jeffrey L. Larson et al.   TOXICOLOGICAL SCIENCES

Drugs in Development for Influenza

(2010) David A. Boltz et al.   DRUGS

A Recombinant Sialidase Fusion Protein Effectively Inhibits Human Parainfluenza Viral Infection In Vitro and In Vivo

(2010) Anne Moscona et al.   JOURNAL OF INFECTIOUS DISEASES

Incidence and morbidity of human metapneumovirus and other community-acquired respiratory viruses in lung transplant recipients

(2010) A. Weinberg et al.   Transplant Infectious Disease

DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis

(2009) Gallen B. Triana-Baltzer et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY